Search results for:
Corporate and Trading Update
Significant revenue growth and commercial momentum Vancouver, British Columbia, Canada - April 24, 2024 Ondine Biomedical (LON: OBI), a leading provider of light-activated antimicrobial technology to treat and prevent hospital infections, provides an update on its recent developments, strategic priorities and 2024 corporate plans. Commercial [...]
Steriwave in first Australian hospital
Mater Hospital, North Sydney has become the first Australian hospital to use Ondine Biomedical’s award-winning light-activated antimicrobial technology Vancouver, British Columbia, Canada - April 22, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Mater Hospital, North [...]
32% Fewer SSIs After Steriwave Replaced Mupirocin
New data shows reduced cardiac infections and significant cost savings after the light-activated antimicrobial, Steriwave, replaced the antibiotic standard of care at the Mazankowski Alberta Heart Institute Vancouver, British Columbia, Canada - April 15, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering [...]
Steriwave authorized for use by HCA UK
Steriwave approved for use in healthcare facilities operated by leading private healthcare provider HCA Healthcare UK Vancouver, British Columbia, Canada - April 10, 2024 Leading private healthcare provider, HCA Healthcare UK, has approved the Steriwave® light-activated antimicrobial developed by Ondine Biomedical Inc. (LON:OBI) for use in [...]
Entry into ICU market expands revenue potential
Following interest from Canadian Hospitals, Ondine prepares to enter the Intensive Care Unit (ICU) market Vancouver, British Columbia, Canada - April 4, 2024 Treatment of patients in ICUs would significantly expand Ondine’s potential market opportunity. Hundreds of thousands of patients are admitted to the ICU [...]
Steriwave study shows 77% drop in antibiotic use
Steriwave study shows 77% drop in antibiotic use Vancouver, British Columbia, Canada - March 21, 2024 Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments to prevent and treat healthcare-associated infections (HAIs), announces that a UK-based study demonstrated a significant reduction [...]
Steriwave deploying in eight new sites
Steriwave deploying in eight new sites Vancouver, British Columbia, Canada - March 15, 2024 Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments to prevent and treat healthcare-associated infections (HAIs), has made significant commercial progress to date in 2024, ahead of [...]
Ondine starts first UK health economics study
The York Health Economics Consortium will undertake the first UK health economic analysis of Ondine’s Steriwave light-activated antimicrobial to reduce surgical site infections Vancouver, British Columbia, Canada - March 5, 2024 Ondine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire and Humber are [...]
Microbiome research supports use of Steriwave
Ondine Biomedical demonstrated that photodisinfection does not harm the nasal microbiome Vancouver, British Columbia, Canada - January 31, 2024 Research presented by Canadian life sciences company, Ondine Biomedical Inc. (LON:OBI), at the prestigious SPIE Photonics West conference in San Francisco, California shows that treatment with [...]
Ondine unveils new research at SPIE Photonics West
Ondine unveils new research at SPIE Photonics West Vancouver, British Columbia, Canada - January 26, 2024 Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present new research at the SPIE Photonics West conference in San Francisco, California. The presentation will provide details of an exploratory [...]
For Media Information
Simon Vane Percy
Amanda Bernard
